This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough. Cathie Wood recently added to her position in CRISPR Therapeutics stock. Barchart · Mar 20
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch. MarketBeat · Feb 19
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025 Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. MarketBeat · Jan 7, 2025
3 Cathie Wood Stocks Analysts Like Better Than Tesla While Ark Invest scoops up Tesla, these three Cathie Wood picks have higher analyst ratings than the struggling EV leader. Barchart · Apr 21, 2024
1st gene-edited snakes use mysterious 'Turing patterns' to achieve near-perfect hexagonal scales Scientists used CRISPR editing to make the world's 1st genetically modified snakes, giving new insight into how the reptiles develop their patterned scales LiveScience · Jun 19, 2023